Is GLP-1 (7-37) FDA approved?

GLP-1 (7-37) is not evaluated or approved by the FDA. It is discussed for research and educational purposes only, not as medical guidance.

Is Liraglutide FDA approved?

Liraglutide is FDA approved (FDA status current as of 2010-01-25). This regulatory status is provided for research and educational context only.

How is GLP-1 (7-37) administered in research settings?

In research settings, GLP-1 (7-37) is typically administered via the subcutaneous or intravenous routes. PeptideBase does not provide dosing or administration instructions.

How is Liraglutide administered in research settings?

In research settings, Liraglutide is typically administered via the subcutaneous route. PeptideBase does not provide dosing or administration instructions.

Home›Research›Compare›GLP-1 (7-37) vs Liraglutide

Peptide Comparison

GLP-1 (7-37) vs Liraglutide

Q: What is the difference between GLP-1 (7-37) and Liraglutide?

GLP-1 (7-37): Binds GLP-1 receptors in the pancreas, gut, and brain. Stimulates glucose-dependent insulin secretion and suppresses glucagon. Central GLP-1 receptor activation reduces food intake via hypothalamic pathways. Liraglutide: GLP-1 receptor agonist; slows gastric emptying, increases satiety, reduces glucagon secretion

Both are Metabolic peptides.

GLP-1 (7-37)

GLP-1 fragment

Fat LossNot EvaluatedResearch Only

33 providers listed

Full GLP-1 (7-37) profile →

Liraglutide

Victoza

Fat LossFDA ApprovedPrescription

Half-life: 13 hours

51 providers listed

Full Liraglutide profile →

Bottom line

Liraglutide is FDA-approved, while GLP-1 (7-37) is not evaluated — the clearest structural difference between them.

Quick Verdict

GLP-1 (7-37)

Evidence

Emerging Clinical

Half-life

—

Liraglutide

Evidence

Established Clinical

Half-life

13 hours

Which One Should You Choose?

Your goal	Better option
Stronger clinical evidence	Liraglutide
Further along in FDA review	Liraglutide
More provider options (33 vs 51)	Liraglutide

Research summary only — not medical advice. Consult a qualified provider before making any decisions.

Side-by-Side Comparison

GLP-1 (7-37)

Liraglutide

Mechanism Family

Metabolic

Half-life

—

13 hours

FDA Status

not evaluated

approved

Admin Routes

subcutaneous, intravenous

subcutaneous

Availability

Research Only

Prescription

Providers

33 listed

51 listed

FDA Update

—

Jan 2010

Avail. Notes

—

FDA-approved GLP-1 agonist. Victoza (NDA 022341, Jan 2010) for T2D; Saxenda (NDA 206321, Dec 2014) for weight management. Prescription only. Generic liraglutide available (generic Victoza, Dec 2024; generic Saxenda, Aug 2025).

Research Evidence

GLP-1 (7-37)

Emerging ClinicalRCT · 2 key studies · most recent 2026

Liraglutide

Established ClinicalRCT · 15 key studies · most recent 2026

Research Citations

GLP-1 (7-37)

Cohort2026 · Protein Sci

Aggregation-driven expression of liraglutide precursors using engineered mini-tags in Escherichia coli.

RCT1999 · Diabetes Care

GLP-1 treatment of obese patients with type 2 diabetes mellitus: improvement of insulin responsiveness by red…

Liraglutide

RCT2022 · JAMA

Semaglutide vs liraglutide for weight loss in adults with overweight or obesity

RCT2015 · New England Journal of Medicine

A randomized, controlled trial of 3.0 mg of liraglutide in weight management

Cohort2026 · Diabetes Obes Metab

Comparative Effects of Individual Glucagon-Like Peptide-1 Receptor Agonist-Based Medications on Direct Measur…

Review2026 · Diabetes Res Clin Pract

GLP-1 receptor agonists in pediatric obesity and diabetes: a systematic review of efficacy, metabolic effects…

+11 more

About GLP-1 (7-37)

Binds GLP-1 receptors in the pancreas, gut, and brain. Stimulates glucose-dependent insulin secretion and suppresses glucagon. Central GLP-1 receptor activation reduces food intake via hypothalamic pathways.

Research Areas

appetite suppressioninsulin sensitivityblood glucose regulation

About Liraglutide

GLP-1 receptor agonist; slows gastric emptying, increases satiety, reduces glucagon secretion

Research Areas

appetite suppressionweight lossblood sugar regulation

Safety Profile

Information below reflects published research data only — not medical advice. Consult a qualified provider before use.

GLP-1 (7-37)

Absolute Contraindications

Personal or family history of medullary thyroid carcinoma (MTC)Multiple Endocrine Neoplasia syndrome type 2 (MEN 2)Known hypersensitivity to the drug or excipients

Warnings & Cautions

Acute pancreatitisPregnancy (discontinue; not for use in pregnancy)Gallbladder disease / cholelithiasisDiabetic retinopathy complications (reported with GLP-1 receptor agonist use)Severe GI disease / gastroparesis / ileus riskHypoglycemia when combined with insulin or sulfonylureasAcute kidney injury secondary to volume depletion

Class-based (investigational)

Liraglutide

Boxed warning

Risk of thyroid C-cell tumors (dose- and duration-dependent in rodents; human relevance undetermined).

Absolute Contraindications

Personal or family history of medullary thyroid carcinoma (MTC)Multiple Endocrine Neoplasia syndrome type 2 (MEN 2)Known hypersensitivity to the drug or excipients

Warnings & Cautions

Source: FDA label

Suggested Monitoring

Under clinical review

Being verified by our medical team before we display monitoring guidance for this peptide.

Find Providers

Where to source these peptides

Providers offering

GLP-1 (7-37)

33 listed

Browse directory →

Providers offering

Liraglutide

51 listed

Browse directory →

PeptideBase lists providers for educational research purposes only. Always consult a qualified healthcare professional before obtaining or using any peptide.

More Metabolic Comparisons

Browse all peptides →

Educational research tools — not medical advice.